LLY News and Press, Eli Lilly and Company From 03/12/24

2024-03-12 12:28:18 ET Summary iShares Core S&P U.S. Growth ETF implements a systematic strategy based on six valuation and growth metrics. Like most large-cap growth funds, the IUSG ETF is overweight in technology and in its top holdings. Quality metrics are attractive, y...

2024-03-12 03:57:11 ET Summary Lexicon Pharmaceuticals is actively working to create shareholder value by pursuing new indications for the lead drug sotagliflozin. The company reported $0.7 million in Inpefa sales for Q4 2023, below expectations, but these are still early days for...

2024-03-11 11:53:40 ET Summary Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients...

2024-03-11 05:53:32 ET Eli Lilly ( NYSE: LLY ) on Sunday reported robust efficacy data from a study for its atopic dermatitis drug, lebrikizumab.... Read the full article on Seeking Alpha For further details see: Eli Lilly eczema drug shows robust efficacy in peo...

2024-03-10 12:23:46 ET Summary AbbVie's full-year results for 2023 might have been weak, but its price is still up by 15% YTD. The disconnect is explained by the revenue dip because of patent expiration for its blockbuster drug Humira, though revenues-ex Humira saw healthy growth....

2024-03-10 12:16:36 ET Summary First Trust BuyWrite Income ETF is an actively managed fund holding 179 stocks and rolling short positions in S&P 500 call options. FTHI return has been average relative to peers over the last 3 years, but it has outperformed for 12 months. T...

2024-03-09 05:07:00 ET Regardless of your investment style, adding a few pharmaceutical stocks to your portfolio is a great idea. These players offer you a certain amount of stability because, no matter what's happening in the general economy, people always need their medicines. This genera...

2024-03-09 04:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-09 03:59:00 ET Summary Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a healthy recovery. Biot...

2024-03-09 00:20:00 ET Summary The ALS drug (Relyvrio) had been put through a Phase II trial by its developer, Amylyx. Amylyx was already working on a Phase III trial, and they committed to withdrawing the drug if this trial showed no efficacy. Just like with the recent approv...